Drug Trial Radar · NCT03308968
An Efficacy and Safety Study of Fremanezumab in Adults With Migraine
Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
838
Actual
Start
Oct 13, 2017
Primary completion
Oct 2, 2018
Study completion May 29, 2019
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- First posted
- Oct 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of monthly and quarterly subcutaneous (sc) injections of fremanezumab compared with sc injections of placebo in participants with chronic migraine (CM) or episodic migraine (EM) who have responded inadequately to 2 to 4 classes of prior preventive treatments. Approximately equal numbers of participants from each subgroup (CM and EM) are randomized in blinded-fashion 1:1:1 into one of 3 treatments for the subgroup - 2 active treatments and 1 placebo treatment- consisting of monthly injections for 3 months (up to Week 12). Then all participants continue into an open-label extension of 3 months (up to Week 24) during which everyone is administered sc injections of fremanezumab.
Conditions
- Migraine Prophylaxis
Interventions
FremanezumabDrug
Fremanezumab will be administered per dose and schedule specified in the arm.
PlaceboDrug
Placebo matching to fremanezumab will be administered per schedule specified in the arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DB Period: Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of FremanezumabTime frame: Baseline (Day -28 to Day -1), up to Week 12
Locations
113 sites in 14 countries. Site status is shown where the registry gives one.
Teva Investigational Site 14742
Huntsville, Alabama
Teva Investigational Site 14729
Long Beach, California
Teva Investigational Site 14739
San Diego, California
Teva Investigational Site 14843
Santa Monica, California
Teva Investigational Site 14749
Colorado Springs, Colorado
Teva Investigational Site 14758
Maitland, Florida
Teva Investigational Site 14738
Orlando, Florida
Teva Investigational Site 14760
Decatur, Georgia
Teva Investigational Site 14737
Meridian, Idaho
Teva Investigational Site 14730
Chicago, Illinois
Teva Investigational Site 14740
Evanston, Illinois
Teva Investigational Site 14735
Louisville, Kentucky
Teva Investigational Site 14747
Pikesville, Maryland
Teva Investigational Site 14750
Fall River, Massachusetts
Teva Investigational Site 14734
Watertown, Massachusetts
Teva Investigational Site 14731
Ann Arbor, Michigan
Teva Investigational Site 14748
Plymouth, Minnesota
Teva Investigational Site 14746
Omaha, Nebraska
Teva Investigational Site 14754
Berlin, New Jersey
Teva Investigational Site 14752
Albuquerque, New Mexico
Teva Investigational Site 14753
Amherst, New York
Teva Investigational Site 14736
Greensboro, North Carolina
Teva Investigational Site 14741
Greensboro, North Carolina
Teva Investigational Site 14732
Raleigh, North Carolina
Teva Investigational Site 14761
Lincoln, Rhode Island
Teva Investigational Site 14756
Warwick, Rhode Island
Teva Investigational Site 14745
Memphis, Tennessee
Teva Investigational Site 14743
Nashville, Tennessee
Teva Investigational Site 14733
Austin, Texas
Teva Investigational Site 14751
West Jordan, Utah
Teva Investigational Site 37092
Bruges, Belgium
Teva Investigational Site 37089
Brussels, Belgium
Teva Investigational Site 37091
Hasselt, Belgium
Teva Investigational Site 37090
Liège, Belgium
Teva Investigational Site 54162
Brno, Czechia
Teva Investigational Site 54159
Ostrava, Czechia
Teva Investigational Site 54165
Ostrava-Moravska, Czechia
Teva Investigational Site 54158
Pardubice, Czechia
Teva Investigational Site 54163
Prague, Czechia
Teva Investigational Site 54161
Prague, Czechia
Showing 40 of 113 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.